Tags

Type your tag names separated by a space and hit enter

Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats.
Toxicol Appl Pharmacol. 2019 02 15; 365:30-40.TA

Abstract

BACKGROUND

Since many diabetic patients require combination therapy, the use of herbal remedies with anti-diabetic activity represents a vital option in diabetes mellitus (DM) management. It has been reported that quercetin has hypoglycemic alongside anti-inflammatory and antioxidant activities.

AIM

The present study aimed to investigate the effectiveness of combining quercetin with sitagliptin; a selective dipeptidyl peptidase-IV (DPP-IV) inhibitor, in the management of streptozotocin (STZ)-induced diabetic rats.

METHODS

DM was induced by a single injection of STZ (45 mg/kg, i.p.) in male adult albino Wistar rats. Diabetic rats were orally treated with sitagliptin (70 mg/kg), quercetin (50 mg/kg) or their combination daily for three consecutive weeks. Serum levels of glucose, C-peptide, total cholesterol, triglycerides, malondialdehyde (MDA), superoxide dismutase, (SOD), reduced glutathione (GSH), tumor necrosis factor alpha, (TNF-α), nuclear factor kappa-B, (NF-κB) and adiponectin were estimated. In addition, histopathological, morphometrical and immunohistochemical examinations of pancreatic tissues were conducted.

RESULTS

The combined administration of quercetin and sitagliptin normalized serum C-peptide, MDA, and significantly increased SOD, GSH and decreased NF-κB more than sitagliptin alone. Moreover, this combination normalized Islet number, β-cells' number, area and perimeter alongside restoring the immunostaining intensity of β-cells.

CONCLUSION

Our results suggest the use of quercetin/sitagliptin combination for treating DM based on the observed improvements in glycemic control, metabolic profile, oxidative and inflammatory status, islet structure as well as β-cells function compared with either treatment alone.

Authors+Show Affiliations

Medicinal and Pharmaceutical Chemistry Department, Pharmacology Group, National Research Centre, Dokki, Giza, Egypt. Electronic address: Noha.fawzy@pharma.cu.edu.eg.Medicinal and Pharmaceutical Chemistry Department, Pharmacology Group, National Research Centre, Dokki, Giza, Egypt.Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Giza, Egypt.Pathology Department, National Research Centre, Dokki, Giza, Egypt.Pathology Department, National Research Centre, Dokki, Giza, Egypt.Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Giza, Egypt.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30576699

Citation

Eitah, Hebatollah E., et al. "Modulating Impacts of Quercetin/sitagliptin Combination On Streptozotocin-induced Diabetes Mellitus in Rats." Toxicology and Applied Pharmacology, vol. 365, 2019, pp. 30-40.
Eitah HE, Maklad YA, Abdelkader NF, et al. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats. Toxicol Appl Pharmacol. 2019;365:30-40.
Eitah, H. E., Maklad, Y. A., Abdelkader, N. F., Gamal El Din, A. A., Badawi, M. A., & Kenawy, S. A. (2019). Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats. Toxicology and Applied Pharmacology, 365, 30-40. https://doi.org/10.1016/j.taap.2018.12.011
Eitah HE, et al. Modulating Impacts of Quercetin/sitagliptin Combination On Streptozotocin-induced Diabetes Mellitus in Rats. Toxicol Appl Pharmacol. 2019 02 15;365:30-40. PubMed PMID: 30576699.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats. AU - Eitah,Hebatollah E, AU - Maklad,Yousreya A, AU - Abdelkader,Noha F, AU - Gamal El Din,Amina A, AU - Badawi,Manal A, AU - Kenawy,Sanaa A, Y1 - 2018/12/19/ PY - 2018/07/15/received PY - 2018/12/14/revised PY - 2018/12/17/accepted PY - 2018/12/24/pubmed PY - 2019/8/20/medline PY - 2018/12/22/entrez KW - Adiponectin KW - Diabetes mellitus KW - Oxidative stress KW - Pancreatic islets KW - Quercetin KW - Sitagliptin SP - 30 EP - 40 JF - Toxicology and applied pharmacology JO - Toxicol Appl Pharmacol VL - 365 N2 - BACKGROUND: Since many diabetic patients require combination therapy, the use of herbal remedies with anti-diabetic activity represents a vital option in diabetes mellitus (DM) management. It has been reported that quercetin has hypoglycemic alongside anti-inflammatory and antioxidant activities. AIM: The present study aimed to investigate the effectiveness of combining quercetin with sitagliptin; a selective dipeptidyl peptidase-IV (DPP-IV) inhibitor, in the management of streptozotocin (STZ)-induced diabetic rats. METHODS: DM was induced by a single injection of STZ (45 mg/kg, i.p.) in male adult albino Wistar rats. Diabetic rats were orally treated with sitagliptin (70 mg/kg), quercetin (50 mg/kg) or their combination daily for three consecutive weeks. Serum levels of glucose, C-peptide, total cholesterol, triglycerides, malondialdehyde (MDA), superoxide dismutase, (SOD), reduced glutathione (GSH), tumor necrosis factor alpha, (TNF-α), nuclear factor kappa-B, (NF-κB) and adiponectin were estimated. In addition, histopathological, morphometrical and immunohistochemical examinations of pancreatic tissues were conducted. RESULTS: The combined administration of quercetin and sitagliptin normalized serum C-peptide, MDA, and significantly increased SOD, GSH and decreased NF-κB more than sitagliptin alone. Moreover, this combination normalized Islet number, β-cells' number, area and perimeter alongside restoring the immunostaining intensity of β-cells. CONCLUSION: Our results suggest the use of quercetin/sitagliptin combination for treating DM based on the observed improvements in glycemic control, metabolic profile, oxidative and inflammatory status, islet structure as well as β-cells function compared with either treatment alone. SN - 1096-0333 UR - https://www.unboundmedicine.com/medline/citation/30576699/Modulating_impacts_of_quercetin/sitagliptin_combination_on_streptozotocin_induced_diabetes_mellitus_in_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0041-008X(18)30558-1 DB - PRIME DP - Unbound Medicine ER -